UPDATE: Stifel Reiterates On HealthSouth As Second Quarter Easily Exceeds Projection
In a report published Tuesday, Stifel analyst Robert Mains reiterated a Buy rating on HealthSouth (NYSE: HLS), and raised the price target from $38.00 to $41.00.
In the report, Stifel noted, “HealthSouth reported second quarter earnings well ahead of our estimate. The company reported income from continuing operations per share (its EPS proxy) of $0.81, beating our $0.65 estimate. Excluding an accounting gain, income from continuing operations per share were $0.54 compared to our at-consensus $0.48 estimate. We are raising our earnings estimate and target price, as the company also increased its guidance.”
HealthSouth closed on Monday at $37.64.
Latest Ratings for HLS
|Jan 2017||PiperJaffray||Initiates Coverage On||Neutral|
|Aug 2016||SunTrust Robinson Humphrey||Maintains||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.